Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of BGB-43395 plus letrozole versus CDK4/6 inhibitor plus letrozole in first-line HR-positive/HER2-negative advanced breast cancer
CTR20262498Phase 3Active
- Sponsor
- BeiGene
- Start
- Jul 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bgb-43395 in breast cancer, sponsored by BeiGene. Started Jul 2026; status: active.
02
Drugs
bgb-43395
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20262498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262498.